Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Samsung launches third rival to AbbVies Humira drug in EU

      Samsung launches third rival to AbbVie's Humira drug in EU

      Medical Dialogues Bureau19 Oct 2018 9:20 AM IST
      LONDON: South Korea's Samsung Bioepis and its partner Biogen have launched a third rival to AbbVie's blockbuster medicine Humira in Europe, ramping up...
      FDA approves Pfizer drug for advanced breast cancer

      FDA approves Pfizer drug for advanced breast cancer

      Medical Dialogues Bureau19 Oct 2018 9:20 AM IST
      Zurich: The U.S. Food and Drug Administration said on Tuesday it approved Pfizer Inc’s drug for an advanced form of breast cancer tied to an inherited...
      Alembic Pharma gets USFDA nod for diabetes drug Alogliptin

      Alembic Pharma gets USFDA nod for diabetes drug Alogliptin

      Medical Dialogues Bureau18 Oct 2018 12:12 PM IST
      New Delhi: Drug firm Alembic Pharmaceuticals Tuesday said it has received tentative nod from the US health regulator for its Alogliptin tablets used...
      Multiple sclerosis drug: US court invalidates Tevas patent; boost for Natco, Mylan

      Multiple sclerosis drug: US court invalidates Teva's patent; boost for Natco, Mylan

      Medical Dialogues Bureau18 Oct 2018 11:50 AM IST
      Copaxone is the most prescribed for relapsing forms of MS in the U.S., with brand sales for the 20 mg/ml dose at approximately $527 million and about...
      Singh brothers, 8 other entities told to repay over Rs 403 crore to Fortis Healthcare: SEBI

      Singh brothers, 8 other entities told to repay over Rs 403 crore to Fortis Healthcare: SEBI

      Medical Dialogues Bureau18 Oct 2018 11:19 AM IST
      New Delhi: Finding alleged diversion of funds, markets regulator Sebi Wednesday directed former promoters of Fortis Healthcare Shivinder Mohan Singh,...
      Bengaluru: Mylan Hackathon 2018 Winners announced

      Bengaluru: Mylan Hackathon 2018 Winners announced

      Medical Dialogues Bureau18 Oct 2018 11:18 AM IST
      BENGALURU: Mylan Pharmaceuticals Private Limited announced the winners of its second edition of the Mylan Hackathon held in Bengaluru. The two-day...
      Dr Reddy donates Rs 25 lakhs to Kerala CM distress Relief fund

      Dr Reddy donates Rs 25 lakhs to Kerala CM distress Relief fund

      Medical Dialogues Bureau18 Oct 2018 9:21 AM IST
      Hyderabad: Telangana-based pharmaceutical company, Dr Reddy’s Laboratories Ltd has donated Rs 25 lakhs to the Kerala Chief Minister Distress Relief...
      Cost of blood pressure drug surges in U.S. after recall

      Cost of blood pressure drug surges in U.S. after recall

      Medical Dialogues Bureau18 Oct 2018 9:20 AM IST
      NEW YORK (Reuters) - Prices for two dosages of the blood pressure drug valsartan rose more than any other drug in the United States in September,...
      Sanofi, Regeneron say late-stage Dupixent trials show positive results in Asthma Treatment

      Sanofi, Regeneron say late-stage Dupixent trials show positive results in Asthma Treatment

      Medical Dialogues Bureau18 Oct 2018 9:14 AM IST
      PARIS, (Reuters) - Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema...
      Sanofi, Novo Nordisk Eli Lilly accused of deceptive drug pricing of Insulin

      Sanofi, Novo Nordisk Eli Lilly accused of deceptive drug pricing of Insulin

      Medical Dialogues Bureau17 Oct 2018 3:16 PM IST
      US : Minnesota's attorney general on Tuesday filed a lawsuit accusing drug manufacturers Sanofi SA, Novo Nordisk and Eli Lilly and Co of deceptively...
      Alembic Pharma gets USFDA nod for diabetes drug

      Alembic Pharma gets USFDA nod for diabetes drug

      Medical Dialogues Bureau17 Oct 2018 3:16 PM IST
      Drug firm Alembic Pharmaceuticals on Tuesday said it has received a tentative nod from the US health regulator for its Alogliptin tablets used for the...
      Haryana: KARNAL to get Mega pharma park, says govt

      Haryana: KARNAL to get Mega pharma park, says govt

      Medical Dialogues Bureau17 Oct 2018 3:10 PM IST
      Chandigarh: The Haryana government Tuesday said a pharma park will be established over 100 acres of land in Karnal.Also, the state's Industries and...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok